Platelet dysfunction in hypercholesterolemia mice, two Alzheimer’s disease mouse models and in human patients with Alzheimer’s disease
Tóm tắt
Alzheimer’s disease (AD) is a severe neurodegenerative disorder characterized mainly by accumulation of amyloid-β plaques and neurofibrillary tangles, synaptic and neuronal loss. Blood platelets contain the neurotransmitter serotonin and amyloid-precursor protein (APP), and may thus be useful as a peripheral biomarker for AD. The aim of the present study was to functionally characterize platelets by FACS, to examine alterations in APP expression and secretion, and to measure serotonin levels in hypercholesterolemia mice with AD-like pathology and in two AD mouse models, the triple transgenic AD model (3xTg) and the APP overexpressing AD model with the Swedish–Dutch–Iowa mutations (APP_SweDI). These data are supplemented with epidermal growth factor (EGF) levels and compared with changes observed in platelets of patients with AD. We observed decreased platelet APP isoforms in 3xTg mice and patients with AD when analysed by means of Western blot. In patients, a significant increase of APP levels was observed when assessed by ELISA. Secreted APPβ proved to be altered amongst all three animal models of AD at different time points and in human patients with AD. Serotonin levels were only reduced in 7 and 14 month old 3xTg mice. Moreover, we found significantly lower EGF levels in human AD patients and could thereby reproduce previous findings. Taken together, our data confirm that platelets are dysfunctional in AD, however, results from AD animal models do not coincide in all aspects, and markedly differ when compared to AD patients. We support previous data that APP, as well as EGF, could become putative biomarkers for diagnosing AD in human platelets.
Tài liệu tham khảo
Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B (1980) Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 27(12):1029–1034
Andersson A, Adolfsson R, Eriksson K, Marcusson J (1991) Platelet [3H]paroxetine binding to 5-HT uptake sites in Alzheimer’s disease. Neurobiol Aging 12(5):531–534
Arora RC, Emery OB, Meltzer HY (1991) Serotonin uptake in the blood platelets of Alzheimer’s disease patients. Neurology 41(8):1307–1309
Bandyopadhyay S, Goldstein LE, Lahiri DK, Rogers JT (2007) Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer’s disease. Curr Med Chem 14(27):2848–2864
Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM (2000) Platelet APP isoform ratios correlate with declining cognition in AD. Neurology 54(10):1907–1909
Björkqvist M, Ohlsson M, Minthon L, Hansson O (2012) Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s disease. PLoS One 7(1):e29868
Blennow K (2005) CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 5(5):661–672
Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6(3):131–144
Borroni B, Colciaghi F, Archetti S, Marcello E, Caimi L, Di Luca M, Padovani A (2004) Predicting cognitive decline in Alzheimer disease. Role of platelet amyloid precursor protein. Alzheimer Dis Assoc Dis 18(1):32–34
Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A (2010) Blood cell markers in Alzheimer disease: amyloid precursor protein form ratio in platelets. Exp Gerontol 45(1):53–56
Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Alzheimer Disease Neuroimaging Initiative, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL (2013) CD33 Alzheimer’s disease locus: altered monocyte function and amyloid biology. Nat Neurosci 16(7):848–850
Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, Currie J, Ames D, Weidemann A, Fischer P et al (1990) The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem 265(26):15977–15983
Casoli T, Di Stefano G, Balietti M, Solazzi M, Giorgetti B, Fattoretti P (2010) Peripheral inflammatory biomarkers of Alzheimer’s disease: the role of platelets. Biogerontology 11(5):627–633
Chasseigneaux S, Dinc L, Rose C, Chabret C, Coulpier F, Topilko P, Mauger G, Allinquant B (2011) Secreted amyloid precursor protein β and secreted amyloid precursor protein α induce axon outgrowth in vitro through Egr1 signaling pathway. PLoS One 6(1):e16301
Chen M, Inestrosa NC, Ross GS, Fernandez HL (1995) Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophy Res Commun 213(1):96–103
Chiu MJ, Yang SY, Horng HE, Yang CC, Chen TF, Chieh JJ, Chen HH, Chen TC, Ho CS, Chang SF, Liu HC, Hong CY, Yang HC (2013) Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer’s disease. ACS Chem Neurosci 4(12):1530–1536
Colciaghi F, Marcello E, Borroni B, Zimmermann M, Caltagirone C, Cattabeni F, Padovani A, Di Luca M (2004) Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer disease. Neurology 62(3):498–501
Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 279(19):20296–20306
Di Luca M, Pastorino L, Cattabeni F, Zanardi R, Scarone S, Racagni G, Smeraldi E, Perez J (1996) Abnormal pattern of platelet APP isoforms in Alzheimer disease and down syndrome. Arch Neurol 53(11):1162–1166
Di Luca M, Pastorino L, Bianchetti A, Perez J, Vignolo LA, Lenzi GL, Trabucchi M, Cattabeni F, Padovani A (1998) Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 55(9):1195–1200
Di Luca M, Colciaghi F, Pastorino L, Borroni B, Padovani A, Cattabeni F (2000) Platelets as a peripheral district where to study pathogenetic mechanisms of alzheimer disease: the case of amyloid precursor protein. Eur J Pharmacol 405(1–3):277–283
Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6(8):734–746
Ehrlich D, Hochstrasser T, Humpel C (2013) Effects of oxidative stress on amyloid precursor protein processing in rat and human platelets. Platelets 24(1):26–36
El Haouari M, Rosado JA (2009) Platelet function in hypertension. Blood Cells Mol Dis 42(1):38–40
Evin G, Zhu A, Holsinger RM, Masters CL, Li QX (2003) Proteolytic processing of the Alzheimer’s disease amyloid precursor protein in brain and platelets. J Neurosci Res 74(3):386–392
Gardella JE, Ghiso J, Gorgone GA, Marratta D, Kaplan AP, Frangione B, Gorevic PD (1990) Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA. Biochem Biophys Res Commun 173(3):1292–1298
Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Investig 115(12):3378–3384
Golde TE, Estus S, Usiak M, Younkin LH, Younkin SG (1990) Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer’s disease using PCR. Neuron 4:253–267
Gowert NS, Donner L, Chatterjee M, Eisele YS, Towhid ST, Münzer P, Walker B, Ogorek I, Borst O, Grandoch M, Schaller M, Fischer JW, Gawaz M, Weggen S, Lang F, Jucker M, Elvers M (2014) Blood platelets in the progression of Alzheimer’s disease. PLoS One 9(2):e90523
Hochstrasser T, Marksteiner J, Humpel C (2012a) Telomere length is age-dependent and reduced in monocytes of Alzheimer patients. Exp Gerontol 47(2):160–163
Hochstrasser T, Ehrlich D, Marksteiner J, Sperner-Unterweger B, Humpel C (2012b) Matrix metalloproteinase-2 and epidermal growth factor are decreased in platelets of Alzheimer patients. Curr Alzheimer Res 9(8):982–989
Hohsfield LA, Ehrlich D, Humpel C (2014) Intravenous infusion of nerve growth factor-secreting monocytes supports the survival of cholinergic neurons in the nucleus basalis of Meynert in hypercholesterolemia brown-Norway rats. J Neurosci Res 92(3):298–306
Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H (2012) Alzheimer’s disease neuroimaging initiative. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79(9):897–905
Hu N, Tan MS, Sun L, Jiang T, Wang YL, Tan L, Zhang W, Yu JT, Tan L (2014) Decreased expression of CD33 in peripheral mononuclear cells of Alzheimer’s disease patients. Neurosci Lett 563:51–54
Humpel C (2011) Identifying and validating biomarkers for Alzheimer’s disease. Trends Biotechnol 29(1):26–32
Inestrosa NC, Alarcón R, Arriagada J, Donoso A, Alvarez J (1993) Platelet of Alzheimer patients: increased counts and subnormal uptake and accumulation of [14C]5-hydroxytryptamine. Neurosci Lett 163(1):8–10
Järemo P, Milovanovic M, Buller C, Nilsson S, Winblad B (2013) P-selectin paradox and dementia of the Alzheimer type: circulating P-selectin is increased but platelet-bound P-selectin after agonist provocation is compromised. Scand J Clin Lab Investig 73(2):170–174
Jarre A, Gowert NS, Donner L, Münzer P, Klier M, Borst O, Schaller M, Lang F, Korth C, Elvers M (2014) Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer’s disease. Cell Signal 26(9):2040–2050
Kassner SS, Bonaterra GA, Kaiser E, Hildebrandt W, Metz J, Schröder J, Kinscherf R (2008) Novel systemic markers for patients with Alzheimer disease?—A pilot study. Curr Alzheimer Res 5(4):358–366
Kokjohn TA, Van Vickle GD, Maarouf CL, Kalback WM, Hunter JM, Daugs ID, Luehrs DC, Lopez J, Brune D, Sue LI, Beach TG, Castaño EM, Roher AE (2011) Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta 1812(11):1508–1514
Koren P, Diver-Haber A, Adunsky A, Rabinowitz M, Hershkowitz M (1993) Uptake of serotonin into platelets of senile dementia of the Alzheimer type patients. J Gerontol 48(3):B93–B96
Kumar AM, Sevush S, Kumar M, Ruiz J, Eisdorfer C (1995) Peripheral serotonin in Alzheimer’s disease. Neuropsychobiology 32(1):9–12
Li QX, Berndt MC, Bush AI, Rumble B, Mackenzie I, Friedhuber A, Beyreuther K, Masters CL (1994) Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer’s disease in human platelet and brain: surface expression on the activated human platelet. Blood 84(1):133–142
Li QX, Fuller SJ, Beyreuther K, Masters CL (1999) The amyloid precursor protein of Alzheimer disease in human brain and blood. J Leukoc Biol 66(4):567–574
Marksteiner J, Humpel C (2013) Platelet-derived secreted amyloid-precursor protein-β as a marker for diagnosing Alzheimer’s disease. Curr Neurovasc Res 10(4):297–303
Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, Oberbauer H, Auffinger S, Hinterhölzl J, Hinterhuber H, Humpel C (2011) Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging 32(3):539–540
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34(7):939–944
Meyerson LR, Strano R, Ocheret D (1989) Diurnal concordance of human platelet serotonin content and plasma alpha-1-acid glycoprotein concentration. Pharmacol Biochem Behav 32(4):1043–1047
Milovanovic M, Eriksson K, Winblad B, Nilsson S, Lindahl TL, Post C, Järemo P (2014) Alzheimer and platelets: low-density platelet populations reveal increased serotonin content in Alzheimer type dementia. Clin Biochem 47(15):51–53
Mimica N, Mück-Seler D, Pivac N, Mustapić M, Dezeljin M, Stipcević T, Presecki P, Radonić E, Folnegović-Smalc V (2008) Platelet serotonin and monoamine oxidase in Alzheimer’s disease with psychotic features. Coll Antropol 32(Suppl 1):119–122
Mönning U, König G, Banati RB, Mechler H, Czech C, Gehrmann J, Schreiter-Gasser U, Masters CL, Beyreuther K (1992) Alzheimer beta A4-amyloid protein precursor in immunocompetent cells. J Biol Chem 267:23950–23956
Muck-Seler D, Presecki P, Mimica N, Mustapic M, Pivac N, Babic A, Nedic G, Folnegovic-Smalc V (2009) Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 33(7):1226–1231
Naert G, Rivest S (2013) A deficiency in CCR2+ monocytes: the hidden side of Alzheimer’s disease. J Mol Cell Biol 5(5):284–293
Neumann K, Farías G, Slachevsky A, Perez P, Maccioni RB (2011) Human platelets tau: a potential peripheral marker for Alzheimer’s disease. J Alzheimers Dis 25(1):103–109
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39(3):409–421
Ogawa T, Sugidachi A, Asai F, Koike H (2000) Reduced platelet serotonin content in rabbits with dietary hypercholesterolemia. Blood Coagul Fibrinolysis 11(4):313–319
Padovani A, Pastorino L, Borroni B, Colciaghi F, Rozzini L, Monastero R, Perez J, Pettenati C, Mussi M, Parrinello G, Cottini E, Lenzi GL, Trabucchi M, Cattabeni F, Di Luca M (2001) Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology 57(12):2243–2248
Patzelt J, Langer HF (2012) Platelets in angiogenesis. Curr Vasc Pharmacol 10(5):570–577
Prokšelj T, Jerin A, Muck-Seler D, Kogoj A (2014) Decreased platelet serotonin concentration in Alzheimer’s disease with involuntary emotional expression disorder. Neurosci Lett 578:71–74
Rainesalo S, Keränen T, Saransaari P, Honkaniemi J (2005) GABA and glutamate transporters are expressed in human platelets. Mol Brain Res 141(2):161–165
Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med 13(11):1359–1362
Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement 5(1):18–29
Rosenberg RN, Baskin F, Fosmire JA, Risser R, Adams P, Svetlik D, Honig LS, Cullum CM, Weiner MF (1997) Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol 54(2):139–144
Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS (1998) Platelet activation in Alzheimer disease. Arch Neurol 55(4):530–536
Shad KF, Aghazadeh Y, Ahmad S, Kress B (2013) Peripheral markers of Alzheimer’s disease: surveillance of white blood cells. Synapse 67(8):541–543
Skovronsky DM, Lee VM, Praticò D (2001) Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 276(20):17036–17043
Smith CC, Betteridge DJ (1997) Reduced platelet serotonin content and release in familial hypercholesterolaemia. Atherosclerosis 130(1–2):87–92
Song F, Poljak A, Smythe GA, Sachdev P (2009) Plasma biomarkers for mild cognitive impairment and Alzheimer’s disease. Brain Res Rev 61(2):69–80
Sparks DL, Scheff SW, Hunsaker JC III, Liu H, Landers T, Gross DR (1994) Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol 126(1):88–94
Srisawat C, Junnu S, Peerapittayamongkol C, Futrakul A, Soi-ampornkul R, Senanarong V, Praditsuwan R, Assantachai P, Neungton N (2013) The platelet amyloid precursor protein ratio as a diagnostic marker for Alzheimer’s disease in Thai patients. J Clin Neurosci 20(5):644–648
Stellos K, Panagiota V, Kögel A, Leyhe T, Gawaz M, Laske C (2010) Predictive value of platelet activation for the rate of cognitive decline in Alzheimer’s disease patients. J Cereb Blood Flow Metab 30(11):1817–1820
Tang K, Hynan LS, Baskin F, Rosenberg RN (2006) Platelet amyloid precursor protein processing: a bio-marker for Alzheimer’s disease. J Neurol Sci 240(1–2):53–58
Tanzi RE, McClatchey AI, Lamperti ED, Villa-Komaroff L, Gusella JF, Neve RL (1988) Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature 331(6156):528–530
Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389
Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, Dang V, Sanchez MM, De Miguel Z, Ashford JW, Salehi A (2013) Ascending monoaminergic systems alterations in Alzheimer’s disease. Translating basic science into clinical care. Neurosci Biobehav Rev 37(8):1363–1379
Tukiainen E, Wikström J, Kilpeläinen H (1981) Uptake of 5-hydroxytryptamine by blood platelets in Huntington’s chorea and Alzheimer type of presenile dementia. Med Biol 59(2):116–120
Ullrich C, Pirchl M, Humpel C (2010) Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits. Mol Cell Neurosci 45(4):408–417
Zainaghi IA, Talib LL, Diniz BS, Gattaz WF, Forlenza OV (2012) Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer’s disease. J Neural Transm 119(7):815–819
Zetterberg H, Blennow K, Hanse E (2010) Amyloid beta and APP as biomarkers for Alzheimer’s disease. Exp Gerontol 45(1):23–29